LTR Pharma researchers have developed a nasal spray aimed at treating erectile dysfunction that proponents claim delivers a response much faster than traditional oral medications. The claim, reported by the Daily Mail portal, describes a potential shift in how men approach sexual health treatments by prioritizing speed and convenience.
Viagra works by triggering a cascade of biochemical events in the body. The medication relaxes the smooth muscle lining the blood vessels of the penis, allowing increased blood flow to produce an erection in response to sexual arousal. This physiologic pathway has been well studied and forms the basis for many current treatments that rely on consistent timing with arousal and activity.
One notable drawback of oral therapies is the typical onset time, which often places the peak effect about an hour after ingestion. For some, planning is necessary to ensure readiness, which can complicate spontaneity in intimate moments.
In contrast, the nasal spray candidate named SPONTAN is presented as a rapid-acting option. Early communications from the developers indicate that erections could occur within as little as 5 to 15 minutes following use, potentially reshaping expectations for timing and immediacy in sexual activity. These early findings suggest a different pharmacokinetic profile compared with oral formulations, offering a faster route to the same therapeutic outcome.
At this stage, the company intends to proceed with larger-scale clinical studies to further evaluate safety, efficacy, and tolerability across a broader population. If the results remain favorable, SPONTAN could be advanced toward regulatory review with a goal of market availability in the near future, with initial projections circulating as early as 2025. The ongoing research underscores the importance of rigorous testing and transparent reporting to ensure informed patient choices and sustained clinical benefit.